Hello my fellow investors.How is everyone doing nowadays? The stock seems to have settled near the $4.4 range and that is a good sign. Not to toot my horns too much,but a HUGE PARTNER has been signed on to bring in the marketing and sales expertise which is required to have a successful commercial launch in the states. There are talks of price management which only seems to benefit the stock holders,since this 'pay per use' device is seeing some huge demand from retail pharma companies (I can't name them here,but you get the point). Be ready to hear abt this news break out in the next couple of weeks or so, unless as I see it some proprietary issues come up.
In short,ALXA is doing everything rgt and as per plans and it is only a matter of time for us to see the benefits. Also, just one piece of advise or forewarning--whatever you wanna call it--there will be a CONCENTRATED effort to bring this below $4 bucks but don;t worry it is the big boys playing it out! dont get fooled into selling as now I have already spilled the beans. :-)
Sentiment: Strong Buy
Dude, garfield is just pumping the stock. He buys it and then pretends to be "in the know". Typical charlatan....there is no fantastic deal coming ALXA's way. Sure, they'll get a deal, but it won't be great terms or anywhere near what they got from BioVail (who got hoodwinked) years ago.
As a reminder, these 2 strategies are: a traditional partnership with a pharmaceutical partner, which would include a typical upfront payment, milestones, royalties and transfer price for the product, or a royalty-based transaction, which will include upfront cash and a revenue stream based on top line ADASUVE sales combined with a partnership of a highly qualified contract sales organization encompassing the field presence, key infrastructure and back office functions that are needed to secure a successful product launch.
Ok folks..ALXA has just wrapped up presentation of their product launch..HUGE HUGE UPSIDE--225M of sales projected in USA ALONE. Vs. 63M..Patient participation request is at an all time high for a startup in the history of pharma launches+ Groupo has pipeline of 100M in 2014 alone for this drug. Combined you are seeing 2014 revenues at 400M. GREAT NEWS AND A GREAT PRESENTATION
Sentiment: Strong Buy
I can tell spring is just around the corner, with all the manure that has been collected, we should have the best garden in the world. That was quite a pant load garf. I got a hand it to you, You can spread the BS pretty well. For Alexza's sake, I am hoping they can come away with some form of success. This company has managed to shoot itself in the foot every chance they get, and hurt a lot of employees and shareholders along the way. This has been the longest 7 years for a start up that I can ever remember. My guess is that a company will make a bid for Alexza, but at a bargain price. The upper management has already sold out.